Skip to main content
SpringerLink
Log in

Keratoprostheses in the Setting of Autoimmune Disorders

  • Chapter
  • First Online:
Keratoprostheses and Artificial Corneas

  • 1074 Accesses

Abstract

Many clinical conditions exist in which standard penetrating keratoplasties are at high risk of failure. These situations require alternative interventions including keratoprostheses. The most challenging of this subset of patients to treat are those with corneal blindness due to autoimmune diseases. Studies have suggested that these patients respond poorly to transplantation due to alterations in corneal tissue at the level of the cellular, microbiological, and immunological microenvironments due to the inflammatory nature of autoimmune-related conjunctivitides. A variety of interventions exist for visual rehabilitation in this patient population depending on the severity of the condition. These options range from artificial keratoprostheses, such as the Boston keratoprosthesis type 1 in patients with a lubricated ocular surface, to the biologic keratoprostheses like the modified osteo-odonto keratoprosthesis (MOOKP) in the most severe autoimmune patients. The current literature suggests that in the setting of autoimmune dysfunction, biological keratoprostheses are far superior to their artificial keratoprosthesis alternatives.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ament JD, Todani A, Pineda R, et al. Global corneal blindness and the Boston keratoprosthesis type I. Am J Ophthalmol. 2010;149:537–9.

    Article  PubMed  Google Scholar 

  2. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Dietrich A, et al. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol. 1995;4(5):313–6.

    Article  CAS  PubMed  Google Scholar 

  4. Oliveira A, et al. O Espectro Clinico Sindrome De Stevens-Johnson E Necrolise Epidermica Toxica. Acta Med Port. 2011;24:995–1002.

    PubMed  Google Scholar 

  5. Fernando SL, et al. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. CMAJ. 2010;182(5):476–80.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, Heng WJ. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527–31.

    Article  CAS  PubMed  Google Scholar 

  7. Zillikens D, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131(8):957–8.

    Article  CAS  PubMed  Google Scholar 

  8. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Bruch-Gerharz D, et al. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol. 2007;17(3):191–200.

    PubMed  Google Scholar 

  10. Chan CC, et al. The modified Cincinnati procedure: combined conjunctival limbal autografts and keratolimbal allografts for severe unilateral ocular surface failure. Cornea. 2012;31:1264–72.

    Article  PubMed  Google Scholar 

  11. Messmer EM, et al. Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications. Ophthalmologe. 2000;97(2):113–20.

    Article  CAS  PubMed  Google Scholar 

  12. Saito T, Nishida K, Sugiyama H, et al. Abnormal keratocytes and stromal inflammation in chronic phase of severe ocular surface diseases with stem cell deficiency. Br J Ophthalmol. 2008;92:404e10.

    Google Scholar 

  13. Dudenhoefer EJ, Nouri M, Gipson IK, et al. Histopathology of explanted collar button keratoprostheses: a clinicopathologic correlation. Cornea. 2003;22:424–8.

    Article  CAS  PubMed  Google Scholar 

  14. Ciralsky J, et al. Keratoprosthesis in autoimmune disease. Ocul Immunol Inflamm. 2010;18(4):275–80.

    Article  PubMed  Google Scholar 

  15. Miri A, Al-Deiri B, Dua HS. Long-term outcomes of autolimbal and allolimbal transplants. Ophthalmology. 2010;117:1207–13.

    Article  PubMed  Google Scholar 

  16. Sant’ Anna AE, Hazarbassanov RM, de Freitas D, Gomes JA. Minor salivary glands and labial mucous membrane graft in the treatment of severe symblepharon and dry eye in patients with Stevens-Johnson syndrome. Br J Ophthalmol. 2012;96:234–9.

    Article  PubMed  Google Scholar 

  17. Biber JM, Skeens HM, Neff KD, et al. The Cincinnati procedure: technique and outcomes of combined living-related conjunctival limbal allografts and keratolimbal allografts in severe ocular surface failure. Cornea. 2011;30:765–71.

    Article  PubMed  Google Scholar 

  18. Magalhães FP, et al. Boston type I keratoprosthesis. Review. Arq Bras Oftalmol. 2012;75(3):218–22.

    Article  PubMed  Google Scholar 

  19. Khan BF, Harissi-Dagher M, Khan DM, Dohlman CH. Advances in Boston keratoprosthesis: enhancing retention and prevention of infection. Int Ophthalmol Clin. 2007;47:61–71.

    Article  PubMed  Google Scholar 

  20. Sejpal K, Yu F, Aldave AJ. The Boston keratoprosthesis in the management of corneal limbal stem cell deficiency. Cornea. 2011;30(11):1187–94.

    PubMed  Google Scholar 

  21. Pujari S, Siddique SS, Dohlman CH, Chodosh J. The Boston keratoprosthesis type II: The Massachusetts Eye and Ear Infirmary experience. Cornea. 2011;30(12):1298–303.

    Article  PubMed  Google Scholar 

  22. Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001;20:19–23.

    Article  CAS  PubMed  Google Scholar 

  23. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008;145:438–44.

    Article  PubMed  Google Scholar 

  24. Jiiraskova N, et al. AlphaCor artificial cornea: clinical outcome. Eye (Lond). 2011;25:1138–46.

    Article  Google Scholar 

  25. Huang Y, Dong Y, Wang L, et al. Long-term outcomes of MICOF keratoprosthesis in the end stage of autoimmune dry eyes: an experience in China. Br J Ophthalmol. 2012;96:28–33.

    Article  PubMed  Google Scholar 

  26. Falcinelli G, Falsini B, Taloni M, Colliardo P, Falcinelli G. Modified osteo-odonto-keratoprosthesis for treatment of corneal blindness: long term anatomical and functional outcomes in 181 cases. Arch Ophthalmol. 2005;123:1319–51329.

    Article  PubMed  Google Scholar 

  27. Tan A, et al. Osteo-odonto keratoprosthesis: systematic review of surgical outcomes and complication rates. Ocul Surf. 2012;10(1):15–25.

    Article  PubMed  Google Scholar 

  28. Michael R, Charoenrook V, de la Paz MF, Hitzl W, Temprano J, Barraquer RI. Long-term functional and anatomical results of osteo- and osteodonto-keratoprosthesis. Graefes Arch Clin Exp Ophthalmol. 2008;246(8):1133–7.

    Article  PubMed  Google Scholar 

  29. Mockenhaupt M. The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803–15.

    Article  PubMed  Google Scholar 

  30. Chan LS. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin Dermatol. 2012;30:34–7.

    Article  PubMed  Google Scholar 

  31. Dohlman JG, Foster CS, Dohlman CH. Boston keratoprosthesis in Stevens-Johnson syndrome: a case of using infliximab to prevent tissue necrosis. Digit J Ophthalmol. 2009;15:1–5.

    Google Scholar 

  32. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology. 1999;106:2136–43.

    Article  CAS  PubMed  Google Scholar 

  33. Araki Y, Sotozono C, Inatomi T. Successful treatment of Stevens–Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147(6):1004–11, 1011.e1.

    Article  CAS  PubMed  Google Scholar 

  34. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–53.

    Article  CAS  PubMed  Google Scholar 

  35. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–9.

    PubMed  Google Scholar 

  36. Traish AS, Chodosh J. Expanding application of the Boston type I keratoprosthesis due to advances in design and improved postoperative therapeutic strategies. Semin Ophthalmol. 2010;25:239–43.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Opthalmology, Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL, 33136, USA

    Matthew J. Weiss MD & Victor L. Perez MD

Authors
  1. Matthew J. Weiss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor L. Perez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor L. Perez MD .

Editor information

Editors and Affiliations

  1. Cornea, External Disease and Refractive Surgery, Department of Ophthalmology and Visual Sciences, University of Illinois Eye and Ear Infirmary, Chicago, Illinois, USA

    M. Soledad Cortina

  2. Cornea, External Disease and Refractive Surgery, Department of Ophthalmology and Visual Sciences, University of Illinois Eye and Ear Infirmary, Chicago, Illinois, USA

    Jose de la Cruz

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weiss, M.J., Perez, V.L. (2015). Keratoprostheses in the Setting of Autoimmune Disorders. In: Cortina, M., de la Cruz, J. (eds) Keratoprostheses and Artificial Corneas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55179-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-55179-6_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-55178-9

  • Online ISBN: 978-3-642-55179-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation